Guselkumab

古塞奇尤单抗

Report date: 2026/05/21 16:40:15
First In Class

Base Information

Drug NameGuselkumab
Drug Alias Name古塞奇尤单抗注射液Guselkumabum谷瑟库单抗Tremphia古塞库人单抗 +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-23 subunit p19 inhibitors
TargetsInterleukin-23 subunit p19
Therapy Area/IndicationsPlaque psoriasisPediatric ulcerative colitisPalmoplantar pustulosis +[23] 
Global Approved IndicationsPsoriasisArthritis, Psoriatic
Approved Indications in ChinaPsoriasis
Original Approved Country/TerritoryUnited States
Original Approved Date2017/07/13
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[61] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMorphosys Ag
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson Innovative MedicineJohnson & Johnson (China) Investment LtdJanssen-Cilag International Nv +[19] 
Inactive CompaniesJanssen IncJanssen-Cilag GmbhThe Rockefeller University +[6] 
Active IndicationsPlaque psoriasisPediatric ulcerative colitisPalmoplantar pustulosis +[19] 
Inactive IndicationsPustular psoriasisLupus NephritisGiant Cell Arteritis +[4] 

Other Information

ATC CodeL04AC16
Related LinksWikipediaDrugBankKEGG